Literature DB >> 25292309

[Prophylaxis of recurrent urinary tract infections].

W Vahlensieck1, H-W Bauer, H J Piechota, M Ludwig, F Wagenlehner.   

Abstract

BACKGROUND: Recurrent urinary tract infections (rUTI), defined as ≥ 3 UTIs per year, mostly affect young and postmenopausal women. Treatable predisposing factors are rare.
METHODS: General recommendations to reduce rUTIs lower the recurrence rate by up to approximately two thirds. Continuous long-term prophylaxis (LP) with low dose antibiotics or single postcoital doses can reduce the recurrence rate of rUTIs to as low as 5%. According to the European Association of Urology guidelines nitrofurantoin, trimethoprim and co-trimoxazole are the first-line drugs and cephalosporins or fluoroquinolones should be restricted to specific indications. Oral and parenteral immunotherapy were found to be effective in several controlled studies for prevention of rUTIs and can be combined with acute antibiotic therapy.
CONCLUSIONS: Vaginal prophylaxis with estriol has proven its positive effect without serious gynecological side effects and there is also increasing evidence that cranberries prevent rUTIs but the exact mode of this therapy remains to be defined. There are also other promising modalities, such as phytotherapeutics, mannose, urine acidification, influencing bacterial intestinal and vaginal flora and the general immune response by e.g. acupuncture and inpatient rehabilitation, the therapeutic value of which still has to be proven.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25292309     DOI: 10.1007/s00120-014-3562-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  35 in total

Review 1.  Oestrogens for preventing recurrent urinary tract infection in postmenopausal women.

Authors:  C Perrotta; M Aznar; R Mejia; X Albert; C W Ng
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 2.  Estrogens and the lower urinary tract.

Authors:  Dudley Robinson; Linda Cardozo
Journal:  Neurourol Urodyn       Date:  2011-06       Impact factor: 2.696

3.  Risk factors for recurrent urinary tract infection in young women.

Authors:  D Scholes; T M Hooton; P L Roberts; A E Stapleton; K Gupta; W E Stamm
Journal:  J Infect Dis       Date:  2000-08-31       Impact factor: 5.226

4.  Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial.

Authors:  Cibele Barbosa-Cesnik; Morton B Brown; Miatta Buxton; Lixin Zhang; Joan DeBusscher; Betsy Foxman
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

5.  Risk factors associated with acute pyelonephritis in healthy women.

Authors:  Delia Scholes; Thomas M Hooton; Pacita L Roberts; Kalpana Gupta; Ann E Stapleton; Walter E Stamm
Journal:  Ann Intern Med       Date:  2005-01-04       Impact factor: 25.391

6.  [Recurrent urinary tract infection in women. Long-term antibiotic prophylaxis].

Authors:  M Ludwig; U Hoyme; W Weidner
Journal:  Urologe A       Date:  2006-04       Impact factor: 0.639

7.  Acupuncture in the prophylaxis of recurrent lower urinary tract infection in adult women.

Authors:  A Aune; T Alraek; H LiHua; A Baerheim
Journal:  Scand J Prim Health Care       Date:  1998-03       Impact factor: 2.581

8.  D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial.

Authors:  Bojana Kranjčec; Dino Papeš; Silvio Altarac
Journal:  World J Urol       Date:  2013-04-30       Impact factor: 4.226

9.  Urinary tract infections in women: etiology and treatment options.

Authors:  Daniele Minardi; Gianluca d'Anzeo; Daniele Cantoro; Alessandro Conti; Giovanni Muzzonigro
Journal:  Int J Gen Med       Date:  2011-04-19

Review 10.  Cranberries for preventing urinary tract infections.

Authors:  Ruth G Jepson; Gabrielle Williams; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17
View more
  1 in total

Review 1.  [Recurrent and catheter-associated urinary tract infections : Prophylaxis and prevention].

Authors:  H Piechota
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.